美国药厂2020元旦再提价，50余种药物受到影响

1月1日标志着新年的开始，标志着新的十年的揭幕，也标志着制药业一些大厂新一轮涨价的来临。

医疗研究机构3 Axis Advisors表示，百时美施贵宝、吉利德科学公司、渤健等制药商在2020年伊始调整了50多种药品的标价。

这次药品的涨幅几乎都不到10%，中位价大约增加了5%，不过未来几周内还有更多药品可能提价。

比起2019年6.3%的平均涨幅，这次提价的幅度相对较低，也低于制药大厂承诺遵守的年均涨价上限10%。政治家们如今已经把药品价格视为2020年美国大选的关键议题。

然而，比起截至2019年11月美国2.1%的年度通胀率，这次提价的幅度还是达到了两倍以上。

虽然与前几年相比，本次提价并不明显，但受到影响的药物仍然可能成为争议点。百时美施贵宝的Opdivo和Yervoy这两款抗癌药和Eliquis这款处方中大量使用的血液稀释剂都变得更加昂贵。而吉利德涨价的则是两款治疗艾滋病的药物Biktarvy和Truvada。

自总统唐纳德·特朗普在18个月前责备药厂“毫无理由”涨价以来，药品价格一直是美国政府的关注点。（财富中文网）

译者：严匡正

The turning of the calendar to January 1st marked a new year, a new decade and new price hikes from some of the pharmaceutical industry’s biggest names.

Bristol-Myers Squibb, Gilead Sciences, Biogen and other drugmakers increased list prices on 50 drugs once 2020 began, according to healthcare research firm 3 Axis Advisors.

The price hikes are almost all below 10%, with the median price increase hovering around 5%, though more price increases could come in the following weeks.

That’s lower than the 2019 average price increase, which came in at 6.3%. And it’s within the 10% annual limit many Big Pharma companies have pledged to honor as politicians zero in on drug pricing as a key talking point in the 2020 election.

It is, however, more than twice the annual inflation rate for the United States, which stood at 2.1% for the 12 months ended November 2019.

While the increases are not excessive, compared to other pharmacological price jumps in previous years, the drugs affected could still be a point of contention. Bristol-Meyers increased the price of Opdivo and Yervoy, two cancer drugs, as well as Eliquis, a heavily prescribed blood thinner. Gilead will charge more for Biktarvy and Truvada, two HIV treatments.

Drug prices have been a focus in Washington for 18 months, after President Doanld Trump chided drug makers for raising prices “for no reason.”